The mission of the Penn ADCC is to increase research and education on AD, related dementias, normal brain aging and mild cognitive impairment (MCI), as well as support development of better diagnostics and preventions/treatments for AD and related disorders. The Penn ADCC provides research training, stimulates new research on normal aging and neurodegenerative dementias as well as development of novel techniques to address the challenges of conducting research on these disorders. The Penn ADCC is a highly interdisciplinary and seamlessly integrated Center with 5 Cores that collaborate extensively with other investigators at and beyond Penn, including the NIH/NIA funded AD Centers (ADCs), NACC, AD Cooperative Study (ADCS), AD Education and Referral (ADEAR) Center, the AD Neuroimaging Initiative (ADNI), AD Genetics Consortium (ADGC) and other NIH/public/private initiatives on AD, related disorders and healthy brain aging.
The Aims of the Penn ADCC are implemented through: 1) Administrative Core A to oversee and direct the activities of the ADCC; 2) Clinical Core B to recruit, follow and study subjects with AD, MCI or related disorders and controls; 3) Data Management and Biostatistics Core C to provide data management and biostatistical expertise; 4) Neuropathology, Genetics and Biomarker Core D to establish postmortem diagnoses on ADCC subjects, and bank CNS tissues, DNA and biofluids from ADCC subjects for diagnostic studies and research; 5) Education, Recruitment and Retention Core E to develop, implement and monitor recruitment and retention programs and ensure that the ADCC team as well as patients and families have up to- date knowledge of AD and related diseases; 6) Pilot Grant Program to stimulate novel research on AD and related disorders; 7) Collaborations with other investigators at and beyond Penn to improve diagnostics and treatments for AD and related disorders as well as increase understanding of these conditions and promote healthy brain aging. In summary, the Penn ADCC contributes to US and global strategies to meet the worldwide challenges of rapidly aging populations and the epidemic of AD and related disorders. In alignment with NIA RFA-AG-11- 005, the Penn ADCC accomplishes its mission in the renewal period through research on AD and related disorders as well as normal aging and through education to increase understanding of these disorders and their global effects.

Public Health Relevance

of the Penn ADCC is that it challenges/re-defines current clinical practice paradigms and research on AD and related disorders as well as MCI and normal aging by utilizing novel concepts and approaches to achieve the goals of this ADCC which are to increase research and education on AD, related dementias, normal brain aging and MCI, as well as support development of better diagnostics and preventions/treatments for AD and related disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010124-25
Application #
8870235
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
1997-07-15
Project End
2016-06-30
Budget Start
2015-07-15
Budget End
2016-06-30
Support Year
25
Fiscal Year
2015
Total Cost
$1,397,996
Indirect Cost
$524,248
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Racine, Annie M; Brickhouse, Michael; Wolk, David A et al. (2018) The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment. Alzheimers Dement (Amst) 10:301-310
Phillips, Jeffrey S; Da Re, Fulvio; Dratch, Laynie et al. (2018) Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiol Aging 63:75-87
Kovacs, Gabor G; Xie, Sharon X; Robinson, John L et al. (2018) Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. Acta Neuropathol Commun 6:50
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Nativio, Raffaella; Donahue, Greg; Berson, Amit et al. (2018) Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease. Nat Neurosci 21:497-505
Roalf, David R; Rupert, Petra; Mechanic-Hamilton, Dawn et al. (2018) Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. J Neurol 265:1365-1375
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Irwin, David J; Xie, Sharon X; Coughlin, David et al. (2018) CSF tau and ?-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology 90:e1038-e1046

Showing the most recent 10 out of 720 publications